EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access · CC BY-NC 4.0

Serial Platelet Function-Guided Antiplatelet Modulation After STEMI: A Randomized Pilot Study

Hrvoje Jurin iD, Irzal Hadžibegović iD, Jure Samardžić, Joško Bulum, Boško Skorić iD, Maja Čikeš, Ivo Planinc, Zvonimir Ostojić, Igor Tagasovski, Davor Miličić

Journal of Cardiovascular Pharmacology and Therapeutics · 2026

DOI: 10.1177/10742484261483397 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Journal of Cardiovascular Pharmacology and Therapeutics, 2026. Verfasst von Hrvoje Jurin und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiovascular Diseases, University Hospital Centre Zagreb (UHC Zagreb), Zagreb, Croatia. Hauptthemen laut MEDLINE: Adenosine Diphosphate, Blood Platelets, Clopidogrel, Platelet Aggregation Inhibitors. Die Arbeit nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Platelet reactivity varies after ST-segment-elevation myocardial infarction (STEMI). We evaluated serial platelet function-guided P2Y12 modulation after a 1-month ticagrelor run-in.

Methods

At month 1, 114 patients were randomized to continued ticagrelor (n=59) or an adenosine diphosphate (ADP)-guided strategy (n=55). Month-1 ADP was the preintervention baseline; months 2, 3, 6, 9, and 12 were analyzed using baseline-adjusted generalized estimating equations. Exploratory net adverse clinical events (NACE) were assessed from randomization through month 12 after STEMI.

Results

In the guided group, month-1 ADP was 52 U (range, 4-466); 37 patients received clopidogrel 75 mg and 18 received 150 mg, with 17 dose-threshold discordances. Adjusted postrandomization ADP was higher with the guided strategy (geometric mean ratio, 1.26; 95% confidence interval [CI], 1.05-1.51). NACE occurred in 14/59 versus 4/55 patients (risk ratio [RR], 0.31; 95% CI, 0.11-0.87; absolute risk difference, -16.5 percentage points; exact P=.020). Any investigator-classified BARC bleeding occurred in 13/59 versus 3/55 (RR, 0.25; 95% CI, 0.07-0.82; exact P=.014), and the post hoc ischemic-or-BARC ≥2 composite in 9/59 versus 2/55 (RR, 0.24; 95% CI, 0.05-1.06; exact P=.055). One ischemic event occurred in each group.

Conclusions

Serial ADP-guided modulation produced pharmacodynamic separation and was associated with fewer investigator-recorded, bleeding-driven events. Dose-threshold deviations, unverified extreme ADP values, incomplete BARC 2 documentation, and only 2 ischemic events restrict interpretation to hypothesis generation; efficacy and safety cannot be established.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Adenosine DiphosphateBlood PlateletsClopidogrelPlatelet Aggregation InhibitorsPurinergic P2Y Receptor AgonistsST Elevation Myocardial InfarctionTicagrelorAgedFemaleHumansMaleMiddle AgedHemorrhagePercutaneous Coronary InterventionPilot ProjectsPlatelet Function TestsProspective StudiesReceptors, Purinergic P2Y12Risk FactorsTime FactorsTreatment Outcome

Stichwörter der Autor:innen

STEMIclopidogrelde-escalationplatelet function testingprimary PCIticagrelor

Substanzen

Adenosine DiphosphateClopidogrelP2RY12 protein, humanPlatelet Aggregation InhibitorsPurinergic P2Y Receptor AgonistsReceptors, Purinergic P2Y12Ticagrelor

Autor:innen und Institutionen

  • Department of Cardiovascular Diseases, University Hospital Centre Zagreb (UHC Zagreb), Zagreb, Croatia.
  • Department of Cardiovascular Diseases, Dubrava University Hospital, Zagreb, Croatia.
  • Faculty of Dental Medicine and Health Osijek, Josip Juraj Strossmayer University of Osijek, Osijek, Croatia.
  • University of Zagreb School of Medicine, Zagreb, Croatia.
  • Algebra Bernays University, Zagreb, Croatia.
  • Magdalena Clinic for Cardiovascular Diseases, Krapinske Toplice, Croatia.

ORCID-Profile: Hrvoje Jurin, Irzal Hadžibegović, Boško Skorić

Zitieren

APA

Jurin, H., Hadžibegović, I., Samardžić, J., Bulum, J., Skorić, B., Čikeš, M., Planinc, I., Ostojić, Z., Tagasovski, I., & Miličić, D. (2026). Serial Platelet Function-Guided Antiplatelet Modulation After STEMI: A Randomized Pilot Study. Journal of Cardiovascular Pharmacology and Therapeutics. https://doi.org/10.1177/10742484261483397

Vancouver

Jurin H, Hadžibegović I, Samardžić J, Bulum J, Skorić B, Čikeš M, et al. Serial Platelet Function-Guided Antiplatelet Modulation After STEMI: A Randomized Pilot Study. Journal of Cardiovascular Pharmacology and Therapeutics. 2026. doi:10.1177/10742484261483397

BibTeX
@article{Jurin2026,
  author = {Jurin, Hrvoje and Hadžibegović, Irzal and Samardžić, Jure and Bulum, Joško and Skorić, Boško and Čikeš, Maja and Planinc, Ivo and Ostojić, Zvonimir and Tagasovski, Igor and Miličić, Davor},
  title = {Serial Platelet Function-Guided Antiplatelet Modulation After STEMI: A Randomized Pilot Study},
  journal = {Journal of Cardiovascular Pharmacology and Therapeutics},
  year = {2026},
  doi = {10.1177/10742484261483397}
}
Kostenlos starten →